hydroxychloroquine has been researched along with Multiple Myeloma in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the effects of autophagy inhibitor ROC-325 and its combination with bortezomib on the proliferation, apoptosis and autophagy of multiple myeloma cell lines." | 4.02 | [The Inhibiting Effect of Autophagy Inhibitor ROC-325 on Multiple Myeloma]. ( Deng, J; Li, ZY; Liu, HM; Shi, MY; Yao, Y; Yuan, CL, 2021) |
| "A 69-year-old female patient with breast cancer experienced severe skin itching and rashes on the face, anterior chest wall, back, and trunk for two days before admission." | 1.72 | A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: A CARE-compliant article. ( Chen, PH; Huang, KP; Lin, CH; Lin, CY; Ni, YL; Tung, HH, 2022) |
| "Multiple myeloma is unique among cancers because proteasomal inhibition has good clinical effects." | 1.43 | Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells. ( Baranowska, K; Bjørkøy, G; Buene, G; Darvekar, S; Holien, T; Johansson, I; Misund, K; Starheim, KK; Sundan, A; Waage, A, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, PH | 1 |
| Tung, HH | 1 |
| Lin, CH | 1 |
| Huang, KP | 1 |
| Ni, YL | 1 |
| Lin, CY | 1 |
| Shi, MY | 1 |
| Yao, Y | 1 |
| Deng, J | 1 |
| Yuan, CL | 1 |
| Liu, HM | 1 |
| Li, ZY | 1 |
| Scott, EC | 2 |
| Maziarz, RT | 1 |
| Spurgeon, SE | 1 |
| Medvedova, E | 1 |
| Gajewski, J | 1 |
| Reasor-Heard, S | 1 |
| Park, B | 1 |
| Kratz, A | 1 |
| Thomas, GV | 1 |
| Loriaux, M | 1 |
| Cascio, M | 1 |
| Podolak, J | 1 |
| Gordon, M | 1 |
| Botelho, J | 1 |
| Stadtmauer, E | 1 |
| Amaravadi, R | 1 |
| Vogl, DT | 2 |
| Tucci, M | 1 |
| Stucci, S | 1 |
| Savonarola, A | 1 |
| Resta, L | 1 |
| Cives, M | 1 |
| Rossi, R | 1 |
| Silvestris, F | 1 |
| Stadtmauer, EA | 1 |
| Tan, KS | 1 |
| Heitjan, DF | 1 |
| Davis, LE | 1 |
| Pontiggia, L | 1 |
| Rangwala, R | 1 |
| Piao, S | 1 |
| Chang, YC | 1 |
| Paul, TM | 1 |
| Nichols, CW | 1 |
| Porter, DL | 1 |
| Kaplan, J | 1 |
| Mallon, G | 1 |
| Bradner, JE | 1 |
| Amaravadi, RK | 1 |
| Baranowska, K | 1 |
| Misund, K | 1 |
| Starheim, KK | 1 |
| Holien, T | 1 |
| Johansson, I | 1 |
| Darvekar, S | 1 |
| Buene, G | 1 |
| Waage, A | 1 |
| Bjørkøy, G | 1 |
| Sundan, A | 1 |
| Alexopoulou, A | 1 |
| Dourakis, SP | 1 |
| Apostolopoulou, A | 1 |
| Kandyli, A | 1 |
| Pandelidaki, H | 1 |
| Archimandritis, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Trial of Hydroxychloroquine Added to Bortezomib for Relapsed/Refractory Myeloma[NCT00568880] | Phase 1 | 25 participants (Actual) | Interventional | 2010-09-08 | Completed | ||
| PATCH 2 & 3: (Prevention and Treatment of COVID-19 With Hydroxychloroquine) A Double-blind Placebo Controlled Randomized Trial of Hydroxychloroquine in the Prevention and Treatment of COVID-19[NCT04353037] | Phase 2 | 39 participants (Actual) | Interventional | 2020-04-07 | Terminated (stopped due to As enrollment began external studies called into question the safety and efficacy of hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy significantly impacted our ability to enroll and retain participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 1-3 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 4 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Rate of negative tests at end of treatment for COVID-19 positive PCR patients in self-quarantine (NCT04353037)
Timeframe: 15-17 days after completion of 14 day treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 6 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Co-inhabitants of COVID-19 positive PCR patients in self-quarantine that test positive up to 31 days after patient begins treatment with HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
if the participant gets COVID and has severe symptoms and hospitalized, end point reached if before the end of the 2 month period (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Rate of COVID-19 infection (confirmed by accepted testing methods) at 2 months (NCT04353037)
Timeframe: Until completion of study, 2 months after start of treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 2 Group 1 (HCQ) | 0 |
| Sub Study 2 Group 2 (Placebo) | 0 |
Number of COVID-19+ PCR patients in self-quarantine who are hospitalized up to 31 days after beginning HCQ or Placebo (NCT04353037)
Timeframe: Until completion of study, 29 to 31 days after beginning treatment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Sub Study 1 Group 1 (HCQ) | 0 |
| Sub Study 1 Group 2 (Placebo) | 0 |
Assessment of any medical events that occur during the ~60 day active period that is felt to be related to receipt of HCQ (NCT04353037)
Timeframe: Until completion of study, 2 months (~60 days) after start of treatment.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| moderate adverse events | minor adverse events | |
| Sub Study 2 Group 1 (HCQ) | 2 | 1 |
| Sub Study 2 Group 2 (Placebo) | 0 | 0 |
1 trial available for hydroxychloroquine and Multiple Myeloma
| Article | Year |
|---|---|
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; D | 2014 |
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; D | 2014 |
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; D | 2014 |
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Boronic Acids; Bortezomib; D | 2014 |
6 other studies available for hydroxychloroquine and Multiple Myeloma
| Article | Year |
|---|---|
A case report of secondary synchronous diagnosis of multiple myeloma and systemic lupus erythematosus after breast cancer treatment: A CARE-compliant article.
Topics: Aged; Antibodies, Monoclonal; Breast Neoplasms; Female; Glycoproteins; Humans; Hydrocortisone; Hydro | 2022 |
[The Inhibiting Effect of Autophagy Inhibitor ROC-325 on Multiple Myeloma].
Topics: Apoptosis; Autophagy; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Hydroxychloroquine; | 2021 |
Double autophagy stimulation using chemotherapy and mTOR inhibition combined with hydroxychloroquine for autophagy modulation in patients with relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Bone Marrow; Cel | 2017 |
An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy | 2014 |
Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Bortezomib; Cell Line, Tumor; Drug Resist | 2016 |
Light chain multiple myeloma in a patient with long-standing rheumatoid arthritis.
Topics: Aged; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Gold Compounds; Hu | 2005 |